Kaitlin Colleen Bevers

Conference Journal of Clinical Oncology · June 1, 2026 e20135Background: B-specific T-cell engagers (BiTEs) such as tarlatamab, have improved upon the efficacy and durability of response in small cell lung cancer (SCLC). However, an unmet need remains due to the known “immune-cold” microenvironment and immune ... Full text Cite

LB4. Patterns and Predictors of Recurrence Following Neoadjuvant Chemoimmunotherapy and Surgery in Non-Small Cell Lung Cancer

Conference The Journal of Thoracic and Cardiovascular Surgery · May 2026 Full text Cite

Exploring salary negotiation and disparities in thoracic surgery

Journal article Jtcvs Open · April 1, 2026 Objective Compensation disparities persist in thoracic surgery, yet the dynamics of salary negotiation remain poorly understood. Exploring surgeon experience with negotiation may identify areas for targeted interventions. Methods An anonymous survey was di ... Full text Cite

Adjuvant Immunotherapy in Lung Cancer: Foundational Successes and Future Directions.

Journal article Thorac Surg Clin · February 2026 This comprehensive article explores the adjuvant use of immunotherapy in resectable lung cancer, specifically highlighting the impact of foundational trials including IMpower010 and KEYNOTE-091. These studies were the first to demonstrate improved survival ... Full text Link to item Cite

Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.

Conference Journal of Clinical Oncology · June 2025 TPS8118Background: The addition of immune checkpoint blockade to neoadjuvant and adjuvant therapy is now standard of care in ... Full text Cite